争夺战升温 诺和诺德再次提高收购Metsera的出价

Core Viewpoint - Novo Nordisk has raised its acquisition bid for obesity startup Metsera in response to Pfizer's increased offer, indicating competitive interest in the company [1] Group 1: Acquisition Bids - Pfizer raised its bid for Metsera to a maximum of $86.2 per share, introducing a "countdown clause" that makes the offer time-sensitive [1] - Novo Nordisk's latest bid matches its previously announced proposal, reflecting its commitment to acquiring Metsera amid competitive pressures [1]